FDA IDE Approval to Initiate a Pivotal Study of the NEXUS Aortic Arch Stent Graft System Has Been Announced
Earlier this year, FDA granted NEXUS™ Aortic Arch Stent Graft System as a breakthrough device.
The designation of NEXUSTM Aortic Arch Stent Graft System as a breakthrough device acknowledges the unmet need in this patient population and the potential for improvements over current standard treatments.
Endospan Receives CE Mark for HORIZON™ EVAR System Based on Robust Clinical and Pivotal Data to Treat Abdominal Aortic Aneurysm
3/21/18: “HORIZON is a unique platform that can be used in a 14Fr single-sided approach, generally shortening and simplifying EVAR procedures,” said Kevin Mayberry, CEO.